Levamisole in Insulin-Dependent Diabetes Mellitus

W. E. Cobb, M. Molitch, S. Reichlin

Research output: Contribution to journalLetter

13 Citations (Scopus)

Abstract

To the Editor: If the hypothesis that human insulin-dependent diabetes mellitus (IDDM) may, in some instances, be an autoimmune disorder is correct, 1 it is reasonable to assume that suppression of the immune response should have a favorable effect on the course of the disorder in some patients. To test this hypothesis we recently studied the effect of levamisole (an agent used successfully in other autoimmune disorders, including rheumatoid arthritis2) on islet-cell function in three young adults with IDDM of three months' duration or less. Levamisole, at the doses used in this study, has been thought to be a stimulator.

Original languageEnglish (US)
Pages (from-to)1065-1066
Number of pages2
JournalNew England Journal of Medicine
Volume303
Issue number18
DOIs
StatePublished - Oct 30 1980

Fingerprint

Levamisole
Type 1 Diabetes Mellitus
Islets of Langerhans
Young Adult

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cobb, W. E. ; Molitch, M. ; Reichlin, S. / Levamisole in Insulin-Dependent Diabetes Mellitus. In: New England Journal of Medicine. 1980 ; Vol. 303, No. 18. pp. 1065-1066.
@article{313cad2a5d97415d8a58e32a0acc617e,
title = "Levamisole in Insulin-Dependent Diabetes Mellitus",
abstract = "To the Editor: If the hypothesis that human insulin-dependent diabetes mellitus (IDDM) may, in some instances, be an autoimmune disorder is correct, 1 it is reasonable to assume that suppression of the immune response should have a favorable effect on the course of the disorder in some patients. To test this hypothesis we recently studied the effect of levamisole (an agent used successfully in other autoimmune disorders, including rheumatoid arthritis2) on islet-cell function in three young adults with IDDM of three months' duration or less. Levamisole, at the doses used in this study, has been thought to be a stimulator.",
author = "Cobb, {W. E.} and M. Molitch and S. Reichlin",
year = "1980",
month = "10",
day = "30",
doi = "10.1056/NEJM198010303031819",
language = "English (US)",
volume = "303",
pages = "1065--1066",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "18",

}

Levamisole in Insulin-Dependent Diabetes Mellitus. / Cobb, W. E.; Molitch, M.; Reichlin, S.

In: New England Journal of Medicine, Vol. 303, No. 18, 30.10.1980, p. 1065-1066.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Levamisole in Insulin-Dependent Diabetes Mellitus

AU - Cobb, W. E.

AU - Molitch, M.

AU - Reichlin, S.

PY - 1980/10/30

Y1 - 1980/10/30

N2 - To the Editor: If the hypothesis that human insulin-dependent diabetes mellitus (IDDM) may, in some instances, be an autoimmune disorder is correct, 1 it is reasonable to assume that suppression of the immune response should have a favorable effect on the course of the disorder in some patients. To test this hypothesis we recently studied the effect of levamisole (an agent used successfully in other autoimmune disorders, including rheumatoid arthritis2) on islet-cell function in three young adults with IDDM of three months' duration or less. Levamisole, at the doses used in this study, has been thought to be a stimulator.

AB - To the Editor: If the hypothesis that human insulin-dependent diabetes mellitus (IDDM) may, in some instances, be an autoimmune disorder is correct, 1 it is reasonable to assume that suppression of the immune response should have a favorable effect on the course of the disorder in some patients. To test this hypothesis we recently studied the effect of levamisole (an agent used successfully in other autoimmune disorders, including rheumatoid arthritis2) on islet-cell function in three young adults with IDDM of three months' duration or less. Levamisole, at the doses used in this study, has been thought to be a stimulator.

UR - http://www.scopus.com/inward/record.url?scp=0019336218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019336218&partnerID=8YFLogxK

U2 - 10.1056/NEJM198010303031819

DO - 10.1056/NEJM198010303031819

M3 - Letter

VL - 303

SP - 1065

EP - 1066

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 18

ER -